Equity Profile

PFE

Pfizer Inc.

Health CarePharmaceuticals$148.0B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for its innovative medicines and vaccines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well Pfizer is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and introduce new products, which is vital for sustaining long-term growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PFE Q2-2026 Earnings Preview

Context

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for its innovative medicines and vaccines. As a key player in the health care sector, Pfizer's performance is closely watched, especially in light of ongoing developments in drug approvals and market demand for health solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+33.22%

Avg Stock Reaction

+0.46%

Last Quarter Recap

In Q1 2026, Pfizer reported an EPS of $0.75, exceeding expectations by 5.63%. The stock saw a modest increase of 0.57% the following day, reflecting a positive market reaction.

Management Promises & Guidance

Continued focus on innovative drug development.
Commitment to maintaining strong profit margins.
Plans to expand vaccine distribution channels.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Pfizer's upcoming earnings report, given its strong track record of beating EPS estimates in recent quarters. However, there is uncertainty regarding revenue figures and overall market conditions.

Bull Case

If Pfizer continues its trend of exceeding EPS estimates, it could signal robust operational efficiency and strong product demand, leading to a positive stock reaction.

Bear Case

Conversely, if revenue growth falls short or management provides cautious guidance, it could lead to a decline in investor confidence and a negative stock response.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Pfizer's history of beating EPS estimates, this figure will be crucial for determining market sentiment and stock performance.

What is the outlook for revenue growth in the upcoming quarters?

Revenue growth is essential for sustaining investor confidence, and any guidance on this will be closely scrutinized.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Pfizer's ability to leverage its existing product portfolio for revenue growth, particularly in the vaccine segment.

Supporting Evidence

Pfizer's recent history of beating EPS estimates suggests stronger operational performance than expected.

The options market is pricing in a significant move, indicating that investors anticipate volatility that could favor a positive outcome.

Key Risk

If revenue growth exceeds expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Pfizer can maintain its strong earnings momentum amid competitive pressures and changing market dynamics.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.70 could indicate underlying issues in profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±9.1%

Historical Avg

±2.3%

Pricing rich

The options market is pricing in a significant potential move for Pfizer's stock, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±9.1% while PFE has averaged ±2.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

16.8%

Calls (3.2M)P/C Ratio: 0.44Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Pfizer beats expectations, history suggests a potential stock increase of around +0.46%, confirming strong operational health.

In-Line / Cautious

A cautious in-line report could lead to muted reactions, as investors weigh management's commentary against current market conditions.

Miss

If Pfizer misses expectations, history suggests a potential decline, with past misses leading to an average drop of around -1.46%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House only

Est. Notional

$103,004.00–$295,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or vaccine developments.
2Management's commentary on cost management strategies.
3Insights into market demand for Pfizer's products.
4Guidance on revenue expectations for the next quarter.
5Responses to competitive pressures in the pharmaceutical market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for its innovative medicines and vaccines....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and will indicate how well Pfizer is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and introduce new products, which is vital for sustaining long-term growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

PFE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+33.22%

Avg Stock Reaction

+0.46%

Last Quarter Recap

In Q1 2026, Pfizer reported an EPS of $0.75, exceeding expectations by 5.63%. The stock saw a modest increase of 0.57% the following day, reflecting a positive market reaction.

Management Promises & Guidance

Continued focus on innovative drug development.
Commitment to maintaining strong profit margins.
Plans to expand vaccine distribution channels.

Expectations

Wall Street Expectations

Bull Case

If Pfizer continues its trend of exceeding EPS estimates, it could signal robust operational efficiency and strong product demand, leading to a positive stock reaction.

Bear Case

Conversely, if revenue growth falls short or management provides cautious guidance, it could lead to a decline in investor confidence and a negative stock response.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given Pfizer's history of beating EPS estimates, this figure will be crucial for determining market sentiment and stock performance.

What is the outlook for revenue growth in the upcoming quarters?

Revenue growth is essential for sustaining investor confidence, and any guidance on this will be closely scrutinized.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Pfizer's ability to leverage its existing product portfolio for revenue growth, particularly in the vaccine segment.

Supporting Evidence

Pfizer's recent history of beating EPS estimates suggests stronger operational performance than expected.

The options market is pricing in a significant move, indicating that investors anticipate volatility that could favor a positive outcome.

Key Risk

If revenue growth exceeds expectations, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Pfizer can maintain its strong earnings momentum amid competitive pressures and changing market dynamics.

Bull Confirmed If

An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.70 could indicate underlying issues in profitability and market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±9.1%

Historical Avg

±2.3%

Pricing rich

The options market is pricing in a significant potential move for Pfizer's stock, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±9.1% while PFE has averaged ±2.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

16.8%

Calls (3.2M)P/C Ratio: 0.44Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Pfizer beats expectations, history suggests a potential stock increase of around +0.46%, confirming strong operational health.

In-Line / Cautious

A cautious in-line report could lead to muted reactions, as investors weigh management's commentary against current market conditions.

Miss

If Pfizer misses expectations, history suggests a potential decline, with past misses leading to an average drop of around -1.46%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House only

Est. Notional

$103,004.00–$295,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug approvals or vaccine developments.
2Management's commentary on cost management strategies.
3Insights into market demand for Pfizer's products.
4Guidance on revenue expectations for the next quarter.
5Responses to competitive pressures in the pharmaceutical market.